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The original article \[[@CR1]\] contained an error in Fig. [7](#Fig7){ref-type="fig"}c whereby the same flow image was accidentally misused for the second and fourth group. The correct version of Fig. [7](#Fig7){ref-type="fig"}c can be viewed below together with the rest of Fig. [7](#Fig7){ref-type="fig"}. Fig. 7CeRNET_CC is sufficient and necessary for six2-induced effects. **a**, **b** Phase contrast images of mammospheres formed by MCF-7-six2 cells with si-CYP4Z1 or si-CYP4Z2P treatment (**a**) and quantification of spheres (**b**). The data are presented as the means ± SDs, *n* = 3, \**P* \< 0.05, \*\**P* \< 0.01 vs. MCF-7-six2. **c** Representative FACS profile of cells described in **a** with CD24− and CD44+ markers. **d**, **e** Cells depicted in **a** were subjected to western blot analysis and followed by detecting the expression of p-Akt/p-ERK1/2 (**e**) and stemness markers (ALDH1 and OCT3/4) (**d**). **f** Images of tumors harvested when MCF-7, MCF-7-six2, MCF-7-six2-si-Z1, and MCF-7-six2-si-Z2P cells (left) and MCF-7-Plko-six2, MCF-7-Plko-six2-Z1-UTR, and MCF-7-Plko-six2-Z2P-UTR cells (right) were planted
